New reporting segments highlight specialty growth despite distribution pressure
- Cencora is a key middleman in the drug supply chain, especially in U.S. pharmaceutical distribution.
- The company introduced a new reporting structure to separate its high-growth specialty services from foundational distribution.
- Fiscal 2027 guidance expects mid-teens operating income growth for the new specialty segment.
- GLP-1 drugs continue lifting sales, but manufacturer price reductions and lower margins remain a headwind.
- Management is clearing out its non-core Other segment, announcing an agreement to sell its equity stake in ProPharma.
A better setup with clear growth engines
Cencora has simplified its story. In Q4 FY2026, management introduced a new two-segment reporting structure separating high-growth specialty services from foundational pharmaceutical distribution. The company is also clearing out its non-core assets, having reached an agreement to sell its equity stake in ProPharma, which effectively empties the former Other segment.
The bull case relies on the margin expansion and visibility of the new specialty segment. Cencora is aggressively scaling its physician services platform, most recently announcing an agreement to acquire a majority interest in American Oncology Network. These higher-margin acquisitions, alongside earlier additions like RCA and OneOncology, help offset pressure in the core distribution business and entrench Cencora in the fastest-growing therapeutic areas.
The bear case centers on structural headwinds in the foundational distribution segment and rising debt. While GLP-1 drugs add billions in revenue, they pressure gross margins, and structural manufacturer list price reductions persist. The core distribution business faces slower growth in fiscal 2027, pressured by previously disclosed customer losses and foreign exchange headwinds. Furthermore, customer concentration with Walgreens Boots Alliance remains a major risk given uncertainty around its new private equity ownership.
This is not a clean bargain story. The company is executing well and returning capital, including a $1.25 billion share repurchase authorization for fiscal 2027. However, the stock price demands consistent earnings growth, and the market will watch closely to see if the foundational distribution segment can reaccelerate after absorbing customer volume shifts in the year ahead.
Moving medicines at huge scale
Cencora makes most of its money by buying medicines and healthcare products, then distributing them to pharmacies, health systems, doctors, and other providers. The business runs on very high sales volume and thin margins, so small changes in product mix or pricing can matter significantly.
Effective fiscal 2027, the company has updated its operating model to two main segments. Specialty Pharmaceutical and Provider Services focuses on high-growth areas like clinical trial logistics and physician management services. This segment aggregates platforms like OneOncology, RCA, and American Oncology Network, which target higher margins in complex care.
Pharmaceutical Distribution and Services is the foundational broad distribution business. It serves health systems, pharmacies, and international wholesale markets. While it generates the vast majority of revenue, growth here is slower, driven by volume increases in categories like GLP-1 medications that offset structural pricing pressures.
Cencora is actively pruning the business. It has entered agreements or completed divestitures for all non-core businesses formerly in its Other category, including an agreement to sell its stake in ProPharma and merge MWI Animal Health with Covetrus. This proves management is willing to exit non-core operations to focus entirely on human health distribution and specialty services.
What flows through Cencora
Brand-name pharmaceuticals
These patented drugs drive high revenue through the massive distribution network, though manufacturer list price reductions can constrain profits.
Generic drugs and biosimilars
Lower-cost versions of older medicines help Cencora maintain its importance to pharmacies and health systems as patents expire.
Specialty pharmaceuticals
Often used for complex diseases, specialty distribution is a high-growth area increasingly supported by clinical logistics and provider services.
GLP-1 diabetes and weight-loss drugs
GLP-1 products continue to add billions in sales volume, though they carry lower gross profit margins than other categories.
Physician services platforms
Acquisitions like RCA, OneOncology, and American Oncology Network give Cencora deeper ties to community specialists and lift overall margins.
Non-core and animal health products
Cencora has agreed to merge MWI Animal Health and divest ProPharma, clearing out non-core assets to focus on its pharmaceutical-centric strategy.
Where revenue comes from
Segment shares use Q4 FY2026 revenue under the prior reporting structure, before intersegment eliminations. Walgreens and Boots together accounted for about 25% of fiscal 2025 revenue.
What could break the story
WBA relationship reset
High impact · Medium oddsWalgreens Boots Alliance and Boots together accounted for about 25% of Cencora revenue in fiscal 2025. WBA was acquired by Sycamore Partners in August 2025, and the new private equity owners could seek changes to long-term agreements. That could affect volumes, pricing, or contract terms.
Lower-margin GLP-1 mix
Medium impact · High oddsGLP-1 drugs are a growth driver, but they have lower gross profit margins. Meanwhile, structural manufacturer list price reductions remain a consistent headwind. If GLP-1s outpace higher-margin areas, margin gains will fade.
Integration of physician networks
High impact · Medium oddsCencora is rapidly expanding its specialty platform through debt-funded acquisitions like OneOncology and a majority stake in American Oncology Network. This introduces substantial integration complexity and leverage risk.
Core distribution slowdown
Medium impact · Medium oddsThe foundational Pharmaceutical Distribution and Services segment faces slower growth, with fiscal 2027 operating income guidance set at 2 to 4 percent due to customer volume shifts and foreign exchange headwinds.
In one breath
What does Cencora actually do?
Cencora distributes medicines and healthcare products to pharmacies, hospitals, doctors, and other providers. It also offers services around specialty drugs, physician practices, and global commercialization.
Why do GLP-1 drugs matter for Cencora?
GLP-1 drugs for diabetes and weight loss are driving massive sales volume through Cencora's network. The catch is that these products carry lower gross profit margins, limiting profit growth.
Why did Cencora change its reporting segments?
In late 2026, Cencora separated its business into a high-growth specialty services segment and a foundational distribution segment. The goal is to provide clearer visibility into its higher-margin specialty engine.
What is the biggest customer risk?
Walgreens and Boots together were about 25% of fiscal 2025 revenue. WBA's acquisition by private equity firm Sycamore Partners adds uncertainty around contract terms, pricing, and volume.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 8, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Internet Content & Information companies
Companies near Cencora, Inc. in Finn's Internet Content & Information industry ranking.

